Status:
COMPLETED
Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Immune Thrombocytopenia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Aims of the study : 1) To determine whether the presence of the V158 allele of Fc gammaRIIIA gene is associated with a better outcome of Immune Thrombocytopenia (ITP) in adults and especially with a h...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Primary ITP as defined by the internation consensus on terminology (Rodeghiero et al. Blood 2009) regardless the phase of the disease (newly-diagnosed, persistent of chronic ITP)
- active ITP defined by a platelet count \< 50 x 109/L at time of inclusion with indication for treatment
- Informed consent
Exclusion
- Secondary ITP
Key Trial Info
Start Date :
September 28 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 2 2015
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT02287649
Start Date
September 28 2012
End Date
October 2 2015
Last Update
October 19 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Henri Mondor Hospital
Créteil, France, 94010